Clinical TrialJun 16, 2026, 09:16 AM
Nexalin's DIFS™ Platform Shows 77.8% Anxiety Response Rate in Trial
AI Summary
Nexalin Technology announced that two clinical abstracts showcasing its proprietary DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. Data from an 8-week pilot clinical trial demonstrated a 77.8% anxiety response rate, significant improvements in depressive symptoms and insomnia, and enhanced quality of life, with no serious adverse events. These findings strengthen the scientific viability of Nexalin's non-invasive neurostimulation approach as the company prepares for global commercial initiatives and advances its FDA De Novo regulatory pathway.
Key Highlights
- Two clinical abstracts accepted for presentation at the 2026 NYC Neuromodulation Conference.
- 77.8% anxiety response rate achieved at the end of treatment (Session 20).
- Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 18.30 points by Session 20.
- Hamilton Depression Rating Scale (HAMD) response and remission rates reached 66.7%.
- Pittsburgh Sleep Quality Index (PSQI) scores significantly improved at 8-week follow-up.
- No serious adverse events, seizures, or manic/hypomanic switches were reported.
- Nexalin Gen-2 15 mA device approved in China, Brazil, Oman, and Israel.
Price Impact
More from NXL